Anti VRK1 - Cosmo Bio Co.,Ltd.

Antibodies

>  

Anti VRK1 Antibody

Catalog No.: BAM-71-600-EX
Size: 100UG
Price: ¥33000
$440
antigen/source: VRK1
host: Mouse
Label: Unlabeled
Purity: Purified
Application: Western Blot
Enzyme Linked Immunosorbent Assay
Immunohistochemistry
Immuno Fluorescence
Immunoprecipitation
Storage: -20C
@
Immunogen: Human
Isotype: IgG1
Clone: 5D1
Reacts with: Human
Purpose: Western blotting: 1/200-1/1000.
Highly sensitive chemiluminescence reagents such as Lumi-Light Plus (Roche), ImmunoStarRLD, or ImmunoStarR Zeta (Wako, Osaka) are recommended.
Immunoprecipitation: assay dependent
Immunofluorescence staining: 1/100
Immu

Other:

 Background 
The VRK1 gene encodes serine/threonine kinase VRK1 (Vaccinia-Related Kinase 1; 396 aa, 45.5 kDa) which is involved in Golgi disassembly during the cell cycle following phosphorylation by PLK3 during mitosis, and required to induce Golgi fragmentation. It acts by mediating phosphorylation of a downstream target protein 'Thr-18' of p53/TP53 and may thereby prevent the interaction between p53/TP53 and MDM2. It also phosphorylates casei and histone H3. Phosphorylation of the BANF1 gene product disrupts its ability to bind DNA, reduces its binding to LEM domain-containing proteins and causes its relocalization from the nucleus to the cytoplasm. Involvement in disease Defects in VRK1 are the cause of pontocerebellar hypoplasia type 1A (PCH1A); also called pontocerebellar hypoplasia with infantile spinal muscular atrophy or pontocerebellar hypoplasia with anterior horn cell disease. PCH1A is characterized by an abnormally small cerebellum and brainstem, central and peripheralmotor dysfunction from birth, gliosis and anterior horn cell degeneration resembling infantile spinal muscular atrophy.
 Cross reactivity 
Human VRK1 protein.
Not tested with other species.




 IMAGE1



Fig.1. Western blot detection of VRK1 in the crude extracts of human cells. Lanes 1, 2, 3; HeLa cell extract (5x10##4### cells) with antibody dilutions at 1/100, 1/500, 1/1000. Lanes 4, 5, 6; U2OS cell extract (5x10##4### cells) with the antibody dilutions at 1/100, 1/500, 1/1,000. As secondary antibody, Alexa488 conjugated goat anti-mouse IgG was used. ImmunoStar(R) LD (Wako, Osaka) was used as chemiluminescence reagent and images were taken with BIO-RAD ChemiDocXRS.

 IMAGE2



Fig.2. Inhibition of VRK1 expression in human cells by RNAi. specific to VRK1. Lane 1; Luciferase RNAi (control). Lane2; VRK1-1 RNAi. Lane 3; VRK1-2 RNAi. Antibody at 1/500 dilution. Lumi-Light Plus (Roche) was used as chemiluminescence reagent. Extracts from 5x10##4### cells.

 IMAGE3



Fig.3. Immunoflorescence staining of VRK1 in HeLa cells. Left; Interphase cells fixed with paraformaldehyde and stained with the antibody at 1/100 dilution. Right; Metaphase cells. At metaphase, VRK1 dots were detected solely in nuclei.

 IMAGE4



Fig.4 Immunofluorescence staining of VRK1 in Hela cells. Left; Interphase cells fixed with methanol and stained with the antibody at 1/100 dilution. Right; Metaphase cells.

 IMAGE5



Fig.5. Immunofluorescence staining of VRK1 in U2OS cells. Left; Interphase cells fixed with paraformaldehyde and stained with the antibody at 1/100 dilution. Right; Metaphase cells.

 IMAGE6



Fig.6. Immunofluorescence staining of VRK1 in U2OS cells. Left; Interphase cells fixed with methanol and stained with the antibody at 1/100 dilution. Right; Metaphase cells.
 
>